Citation Impact
Citing Papers
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
2016
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
2019
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
2016
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials
2018
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression
2019 Standout
Gastric cancer
2016 Standout
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
2020
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
2017
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
A view on drug resistance in cancer
2019 StandoutNature
Vessel co-option in cancer
2019
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
2015
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
2019
New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression
2018
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
2016
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
2014
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
2018
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Ten years of anti-vascular endothelial growth factor therapy
2016
Colorectal cancer
2019 Standout
Cancer-associated cachexia
2018 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial
2019
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Gastric cancer
2020 Standout
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
2016
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Antiangiogenic therapy in oncology: current status and future directions
2016
Unmet needs and challenges in gastric cancer: The way forward
2014
Advanced gastric cancer: Current treatment landscape and future perspectives
2016
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Noncoding RNAs in gastric cancer: implications for drug resistance
2020
Updates on Management of Gastric Cancer
2019
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
2016
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies
2016
Chemotherapy for advanced gastric cancer
2017 Standout
Anti-Angiogenics: Current Situation and Future Perspectives
2018
Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma
2017
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Update on Metastatic Gastric and Esophageal Cancers
2015
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
2018
Works of Roberto Carlesi being referenced
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).
2014
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer
2015